Heart meds, digital therapeutics highlight day three of JP Morgan ‘19
Day three at the JP Morgan Healthcare Conference included insights from executives at Amarin and Pear Therapeutics.
Most recent articles by Laura Entis
Drug prices, digital partnerships, diversity take center stage on day two of JP Morgan ‘19
Meanwhile, an upstart conference made its mark nearby.
Day one at JP Morgan ‘19: Mega-deals, accessibility, and price gouging (by hotels)
Deals, access and pricing, and the cost of attending one of healthcare’s biggest events ruled day one buzz at the conference.
Co-pay accumulators: A force to be reckoned with in 2019
Experts predict the controversial tactic will be deployed far more widely this year, significantly impacting manufacturers — and, whether or not they realize it yet, patients.
How to lower drug prices in the U.S.? Lots of suggestions, few viable solutions
A panel representing pharma, government payer, and policy analyst presented three potential big-picture goals to strive for.
Five things for pharma marketers to know: Tuesday, October 30, 2018
The rise and fall of Dr. Piero Anversa; Database of retracted scientific papers posted; Why PhRMA is worried about a “blue wave.”
Five things for pharma marketers to know: Monday, October 29, 2018
2018 Health Influencer 50; Have we reached peak CBD?; Justice Department reaches $25 million settlement with Abbott, AbbVie.
CEO: Marketing plan for anti-epileptic aims to distinguish it from sea of other cannabis drugs
A central component of the Epidiolex marketing strategy involves highlighting the drug’s efficacy and safety profile, not its precedent-setting CBD component.
Five things for pharma marketers to know: Tuesday, October 23, 2018
Governments push back against Philip Morris non-cigarette products; California judge reduces weedkiller suit penalties against Bayer; Teens account for one-quarter of Juul’s Twitter following.
Five things for pharma marketers to know: Monday, October 22, 2018
Study finds immune-based treatment effective against some breast cancers; Former FDA commissioners advocate the agency should be independent; Philip Morris’ new ad urges users to quit smoking
